Select Bibliography

Select Bibliography

Filter by any of these (after searching):

Federally Funded Research

There are 57 items

NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)--interim review of toxicity

Google Scholar

Alberts, S. R. , Morlan, B. W. , Kim, G. P. , Pitot, H. C. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007

Abstract - Primary Endpoint - Preliminary Analysis - GI - NCCTG-N044J

Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data

PubMed

PMC

QxMD

Google Scholar

Apoe, Ogheneruona , Jung, Sin-Ho , Liu, Heshan , Seisler, Drew K ... - - Am J Hematol Oncol - 2016

Manuscript - Primary Endpoint - Preliminary Analysis - Prevention - CALGB-70806

Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502

Google Scholar

Attar, E. C. , Donohue, K. A. , Amrein, P. C. , Wadleigh, M. ... - - Blood - 2010

Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - CALGB-10502

Phase IB study of sorafenib + evofosfamide in patients with advanced hepatocellular carcinoma (HCC) and renal cell carcinoma NCCTG N1153 (Alliance)

Google Scholar

Borad, Mitesh J. , Foster, Nathan R. , Martin, Peter R. ... - ESMO GI - Ann. Oncol. - 2016

Abstract - Primary Endpoint - Preliminary Analysis - Experimental - N1153

Preliminary safety data of a randomized phase III trial comparing a preoperative regimen of FEC-75 alone followed by paclitaxel plus trastuzumab with a regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER2-positive operable breast cancer (ACOSOG Z1041)

Google Scholar

Buzdar, A. U. , Meric-Bernstam, F. , Boughey, J. C. , Leitch, A. M. ... - - J. Clin. Oncol. - 2010

Abstract - Secondary Endpoint - Preliminary Analysis - Breast - ACOSOG-Z1041

Allosteric Akt inhibitor MK2206 synergizes with bendamustine in promoting the apoptosis of chronic lymphocytic leukemia cells and selectively targets B-cell receptor mediated cytokine production

Google Scholar

Ding, W. , Shanafelt, T. D. , Lesnick, C. , Sassoon, T. , Secreto, C. ... - ASH - Blood - 2012

Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - N1087

The Impact of Adjuvant Brachytherapy with Sublobar Resection on Pulmonary Function and Dyspnea: Preliminary Results from ACOSOG Z4032 Trial

Google Scholar

Fernando, H. C. , Landreneau, R. , Mandraker, S. , Hillman, S. ... - AATS - American Association of Thoracic Surgery 90th Annual Meeting - 2010

Abstract - Primary Endpoint - Preliminary Analysis - Respiratory - ACOSOG-Z4032

A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2N0 Rectal Cancer: Preliminary Results of the ACOSOG Z6041 Trial

PubMed

PMC

QxMD

DOI

Google Scholar

Garcia-Aguilar, Julio , Shi, Qian , Thomas, Charles R. , Chan, Emily ... - - Ann. Surg. Oncol. - 2012

Manuscript - Primary Endpoint - Preliminary Analysis - GI - ACOSOG-Z6041

Initial results of CALGB 80803: A randomized phase II trial of pet scan-directed combined modality therapy for esophageal cancer (Alliance)

Google Scholar

Goodman, Karyn A. , Niedzwiecki, Donna , Hall, Nathan ... - ASCO GI - J Clin Oncol - 2017

Abstract - Primary Endpoint - Preliminary Analysis - GI - CALGB-80803

A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non small cell lung cancer: CALGB 30407 early evaluation of feasibility and toxicity

Google Scholar

Govindan, R. , Bogart, J. A. , Wang, X. , Liu, D. , Kratzke, R. A. ... - - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Preliminary Analysis - Respiratory - CALGB-30407

Associations of Physical Activity with Survival and Progression in Metastatic Colorectal Cancer: Results from CALGB 80405 (Alliance)

Google Scholar

Guercio, Brendan J. , Venook, Alan P. , Niedzwiecki, Donna ... - ASCO GI - J Clin Oncol - 2017

Abstract - Secondary Endpoint - Preliminary Analysis - GI - CALGB-80405

Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.

PubMed

DOI

Google Scholar

Hurwitz, Mark D , Halabi, Susan , Ou, San-San , McGinnis, Lamar S ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2008

Manuscript - Primary Endpoint - Preliminary Analysis - GU - CALGB-99809

Comparison of MRI endpoints for assessing breast cancer response to neoadjuvant treatment: preliminary findings of the American College of Radiology Imaging Network (ACRIN) trial 6657

Google Scholar

Hylton, N. M. , Blume, J. , Bernreuter, W. , Pisano, E. , Rosen, M. ... - - Cancer Res. - 2009

Abstract - Primary Endpoint - Preliminary Analysis - Breast - CALGB-150007

MRI Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy: Preliminary Findings of the American College of Radiology Imaging Network (ACRIN) Trial 6657

Google Scholar

Hylton, N. M. , Blume, J. , Bernreuter, W. , Pisano, E. , Rosen, M. ... - RSNA - Radiological Society of North America 94th Scientific Assembly and Annual Meeting - 2008

Abstract - Primary Endpoint - Preliminary Analysis - Breast - CALGB-150007

NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study

Google Scholar

Jaeckle, K. A. , Schiff, D. , Anderson, S. K. , Galanis, E. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Primary Endpoint - Preliminary Analysis - Neuro-Onc - N0572

Phase I/II trial of sorafenib and CCI-779 in patients with recurrent glioblastoma (GBM)

Google Scholar

Jaeckle, K. , Anderson, K. , Sarkaria, J. , Decker, P. , Buckner, J. ... - ICTT - - 2008

Abstract - Primary Endpoint - Preliminary Analysis - Neuro-Onc - NCCTG-N0572

A phase I/II trial adding the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel in patients with locoregionally advanced squamous cell carcinoma of the head and neck (HNSCC) Alliance A091101

DOI

Google Scholar

Jelinek, Michael J. , Foster, Nathan R. , Zoroufy, Alex J. ... - ASCO - J Clin Oncol - 2018

Abstract - Primary Endpoint - Preliminary Analysis - Experimental - A091101

Combination of everolimus with R-CHOP (ever R-CHOP) as an initial therapy for diffuse large B cell lymphoma (DLBCL): NCCTG N1085 (Alliance) phase I and feasibility study

Google Scholar

Johnston, Patrick B. , LaPlant, Betsy R. , Nowakowski, Grzegorz S. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Preliminary Analysis - Lymphoma - N1085

Everolimus plus R-CHOP as initial therapy for DLBCL: a phase I/feasibility study (NCCTG N1085 [Alliance])

Google Scholar

Johnston, Patrick B. , LaPlant, Betsy R. , Nowakowski, Grzegorz S. ... - ICML - Hematol Oncol - 2015

Abstract - Primary Endpoint - Preliminary Analysis - Lymphoma - N1085

Bortezomib maintenance (BM) vs consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell (MCL): CALGB 50403 (Alliance).

Google Scholar

Kaplan, L. D. , Jung, S. H. , Bartlett, N. C. , Johnson, J. , Byrd, J. ... - ASH - Hematol Oncol - 2013

Abstract - Primary Endpoint - Preliminary Analysis - Lymphoma - CALGB-50403

A randomized phase II trial of maintenance vs consolidation bortezomib therapy following aggressive chemo-immunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma (MCL): CALGB 50403

Google Scholar

Kaplan, L. D. , Jung, S. , Johnson, J. L. , Linker, C. , Byrd, J. C. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Preliminary Analysis - Lymphoma - CALGB-50403

Pemetrexed, Carboplatin, and Concomitant Radiation followed by Surgery for Locally Advanced Esophageal Cancer: Results of a Planned Interim Toxicity Analysis of North Central Cancer Treatment Group Study N044E

PubMed

PMC

QxMD

Google Scholar

Katipamula, Rajini , Jatoi, Aminah , Foster, Nathan R. ... - - Clin Med Oncol - 2008

Manuscript - Secondary Endpoint - Preliminary Analysis - GI - N044E

Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808

Google Scholar

Kolitz, J. E. , Hars, V. , Deangelo, D. J. , Allen, S. L. ... - - Blood - 2007

Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - CALGB-19808 , CALGB-8461 , CALGB-9665

A phase II trial of carboplatin and ABI-007 in patients with unresectable stage IV melanoma, N057E.

Google Scholar

Kottschade, L. , Suman, V. , Amatruda, T. , Mcwilliams, R. ... - - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Preliminary Analysis - Experimental - N057E

Phase I randomized phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM): Final results of phase I study

Google Scholar

Laack, N. N. , Galanis, E. , Leinweber, C. , Buckner, J. C. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Preliminary Analysis - Neuro-Onc - N0877

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101

Google Scholar

Lin, T. S. , Donohue, K. A. , Lucas, M. S. , Byrd, J. C. ... - - Blood - 2007

Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - CALGB-10101

Randomized phase II study comparing the met inhibitor cabozantinib to temozolomide (tmz) or dacarbazine (dtic) in ocular melanoma - A091201

Google Scholar

Luke, Jason J. , Allred, Jacob B. , Horvath, Laura E. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Preliminary Analysis - Experimental - A091201

Preliminary Analysis of Cancer and Leukemia Group B (CALGB) 80003: A Phase II Trial of Gemcitabine, 5-Fluorouracil (5FU), and Radiation Therapy (RT) in Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma

Google Scholar

Mamon, H. J. , Niedzwiecki, D. , Hollis, D. R. , Tan, B. , Smith, J. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2005

Abstract - Primary Endpoint - Preliminary Analysis - GI - CALGB-80003

CALGB 50803 (Alliance): A phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma

Google Scholar

Martin, P. , Jung, S.-H. , Johnson, J. , Elstrom, R. , Bartlett, N. L. ... - ICML - Hematol Oncol - 2013

Abstract - Primary Endpoint - Preliminary Analysis - Lymphoma - CALGB-50803

Phase III intergroup study of lenalidomide (CC-5013) versus placebo maintenance therapy following single autologous stem cell transplant for multiple myeloma (CALGB 100104): Initial report of patient accrual and adverse events

Google Scholar

Mccarthy, P. L. , Linker, C. , Hofmeister, C. C. , Owzar, K. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Preliminary Analysis - Transplant - CALGB-100104

N0937 (Alliance): Preliminary results of a phase II clinical trial of cisplatin and the novel agent brostallicin in patients with metastatic triple negative breast cancer (mTNBC)

Google Scholar

Moreno-Aspitia, A. , Rowland, K. M. Jr , Allred, J. B. , Liu, H. ... - AACR - Cancer Res. - 2012

Abstract - Primary Endpoint - Preliminary Analysis - Breast - N0937

A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis.

Google Scholar

Morrison, V. A. , Johnson, J. L. , Jung, S. , Leonard, J. P. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Preliminary Analysis - Lymphoma - CALGB-50501

Salvage Therapy with Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Initial Results of a Phase II Trial (Alliance/CALGB 50501)

Google Scholar

Morrison, V. A. , Jung, S.-H. , Johnson, J. , Lacasce, A. ... - ASH - ASH Annual Meeting Abstracts - 2012

Abstract - Primary Endpoint - Preliminary Analysis - Lymphoma - CALGB-50501

Therapy with bortezomib plus lenalidomide is tolerable in patients (pts) with relapsed/refractory mantle cell lymphoma (MCL): Interim results of CALGB 50501

Google Scholar

Morrison, V. A. , Jung, S. , Johnson, J. , Leonard, J. ... - - Ann. Oncol. - 2011

Abstract - Primary Endpoint - Preliminary Analysis - Lymphoma - CALGB-50101

A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501)

Google Scholar

Morrison, V. A. , Jung, S. , Leonard, J. ... - - J. Clin. Oncol. - 2011

Abstract - Primary Endpoint - Preliminary Analysis - Lymphoma - CALGB-50501

Adjuvant targeted therapy following standard adjuvant therapy for resected NSCLC: An initial report from ALCHEMIST (Alliance A151216)

DOI

Google Scholar

Oxnard, Geoffrey R. , Mandrekar, Sumithra , Hillman, Shauna ... - IASLC (WCLC) - J Thorac Oncol - 2018

Abstract - Primary Endpoint - Preliminary Analysis - Respiratory - A151216

The Men’s Eating and Living (MEAL) Study (CALGB 70807 [Alliance]): Recruitment Feasibility and Baseline Demographics of a Randomized Trial of Diet in Men on Active Surveillance for Prostate Cancer

PubMed

PMC

QxMD

DOI

Google Scholar

Parsons, J. Kellogg , Pierce, John P. , Mohler, James ... - - BJU Int. - 2018

Manuscript - Secondary-not-in-original Endpoint - Preliminary Analysis - Prevention - CALGB-70807

A phase II study of neoadjuvant therapy with cisplatin, docetaxel, panitumumab plus radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051)

Google Scholar

Reed, C. , Decker, P. , Schefter, T. , Meyers, B. , Ferguson, M. ... - - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Preliminary Analysis - GI - ACOSOG-Z4051

CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma

Google Scholar

Rini, B. I. , Halabi, S. , Rosenberg, J. E. , Stadler, W. M. ... - ASCO GU - Genitourinary Cancers Symposium - 2008

Abstract - Primary Endpoint - Preliminary Analysis - GU - CALGB-90206

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

PubMed

PMC

QxMD

DOI

Google Scholar

Rini, Brian I. , Halabi, Susan , Rosenberg, Jonathan E. ... - - J Clin Oncol - 2008

Manuscript - Primary Endpoint - Preliminary Analysis - GU - CALGB-90206

The feasibility of breast-conserving surgery for multiple ipsilateral breast cancer: An initial report from ACOSOG Z11102 (Alliance) trial

PubMed

PMC

QxMD

DOI

Google Scholar

Rosenkranz, Kari M. , Ballman, Karla , McCall, Linda ... - - Ann. Surg. Oncol. - 2018

Manuscript - Secondary Endpoint - Preliminary Analysis - Breast - Z11102

Interim analysis of CALGB 150607: A pilot project to study the expression of MET and p53 in resected lung adenocarcinoma specimens

Google Scholar

Salama, A. K. , Kratzke, R. A. , Richards, W. , Pang, H. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Secondary Endpoint - Preliminary Analysis - Correl Sci NOS - CALGB-150607

An Interim Analysis Of CALGB 150607: Expression And Mutational Status Of c-MET, HGF, EGFR, KRAS, p53, c-CBL, And E-cadherin In Resected Lung Adenocarcinoma Specimens

Google Scholar

Salgia, R. , Nallasura, V. , Pang, H. , Rolle, C. , Richards, W. ... - Chicago MSTO - Clin. Cancer Res. - 2012

Abstract - Secondary Endpoint - Preliminary Analysis - Correl Sci NOS - CALGB-150607

Feasibility/tolerability results from a phase I/II study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North Central Cancer Treatment Group (NCCTG) N0572

Google Scholar

Schiff, D. , Sarkaria, J. , Decker, P. , Buckner, J. , Galanis, E. ... - SNO - Neuro-oncology - 2009

Abstract - Primary Endpoint - Preliminary Analysis - Neuro-Onc - N0572

Phase I study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North central cancer treatment group (NCCTG) N0572

Google Scholar

Schiff, D. , Sarkaria, J. , Decker, P. , Buckner, J. , Galanis, E. ... - SNO - Neuro-oncology - 2007

Abstract - Primary Endpoint - Preliminary Analysis - Neuro-Onc - N0572

N0321: A Phase I Study of bortezomib, Paclitaxel, Carboplatin (CBDCA) & Radiotherapy (RT) for Locally-Advanced Non-Small Cell Lung Cancer (NSCLC)

Google Scholar

Schild, S. , Molina, J. , Dy, G. , Rowland, K., Jr , Sarkaria, J. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Preliminary Analysis - Respiratory - NCCTG-N0321

Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 79809

Google Scholar

Shapiro, C. L. , Halabi, S. , Gibson, G. , Friedlander, R. J. ... - - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Preliminary Analysis - Symptom Inter - CALGB-79809

Four vs 6 Cycles of Doxorubicin and Cyclophosphamide (AC) or Paclitaxel (T) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Nodes: CALGB 40101 A 2x2 Factorial Phase III Trial: First Results Comparing 4 vs 6 Cycles of Therapy.

Google Scholar

Shulman, L. N. , Cirrincione, C. T. , Berry, D. A. , Becker, H. P. ... - SABCS - - 2010

Abstract - Primary Endpoint - Preliminary Analysis - Breast - CALGB-40101

Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer

Google Scholar

Sikov, W. , Perou, C. M. , Golshan, M. , Collyar, D. , Berry, D. A. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Preliminary Analysis - Breast - CALGB-40603

Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed/refractory B cell lymphomas: ALLIANCE A051201 and A051202

Google Scholar

Smith, Sonali M. , Pitcher, Brandelyn N. , Jung, Sin-Ho ... - ASH - Blood - 2014

Abstract - Primary Endpoint - Preliminary Analysis - Lymphoma - A051201 , A051202

Favorable outcomes for adolescents and young adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early results of US Intergroup trial CALGB 10403 (Alliance)

Google Scholar

Stock, Wendy , Luger, Selina , Advani, Anjali , Geyer, Susan ... - ASH - Blood - 2014

Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - C10403 , CALGB-10403

CALGB 10603 (RATIFY): A randomized phase III study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naive patients with FLT3 mutated AML

Google Scholar

Stone, R. M. , Dohner, H. , Ehninger, G. , Villeneuve, M. ... - - J. Clin. Oncol. - 2011

Abstract - Secondary Endpoint - Preliminary Analysis - Leukemia - CALGB-10603

Results of US Intergroup Trial of Response-Adapted Chemotherapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)

Google Scholar

Straus, David J. , Pitcher, Brandelyn N. , Kostakoglu, Lale ... - ASH - Blood - 2015

Abstract - Primary Endpoint - Preliminary Analysis - Lymphoma - CALGB-50604

A Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma

DOI

Google Scholar

Ujjani, C. , Cheson, B. D. ... - ICML - Hematol Oncol - 2013

Abstract - Primary Endpoint - Preliminary Analysis - Lymphoma - A051103

Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001)

Google Scholar

Uy, Geoffrey L. , Sanford, Ben , Marcucci, Guido , Zhao, Weiqiang ... - ASH - Blood - 2013

Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - CALGB-11001

Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results

PubMed

Google Scholar

Venook, A. , Niedzwiecki, D. , Hollis, D. , Sutherland, S. ... - ASCO - J. Clin. Oncol. - 2006

Abstract - Primary Endpoint - Preliminary Analysis - GI - CALGB-80203

Interim safety analysis of a phase 2 randomized study of daratumumab (dara), lenalidomide (r), bortezomib (v), and dexamethasone (d; dara‐rvd) vs. rvd in patients (pts) with newly diagnosed multiple myeloma (mm) eligible for high‐dose therapy (hdt) and autologous stem cell transplantation (asct)

Google Scholar

Voorhees, Peter M. , MD , Costa, Luciano J. , PhD , Reeves, Brandi ... - ASH - Blood - 2017

Abstract - Secondary Endpoint - Preliminary Analysis - Myeloma - AFT-29